In Vitro and In Vivo Activity of IMGN853, an Antibody–Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers

Molecular Cancer Therapeutics ◽

10.1158/1535-7163.mct-17-0930 ◽

2018 ◽

Vol 17 (5) ◽

pp. 1003-1011 ◽

Author(s):

Gary Altwerger ◽

Elena Bonazzoli ◽

Stefania Bellone ◽

Tomomi Egawa-Takata ◽

Gulden Menderes ◽

...

Keyword(s):

Folate Receptor ◽

Antibody Drug Conjugate ◽

Folate Receptor Alpha ◽

Receptor Alpha ◽

Drug Conjugate ◽

Endometrial Cancers ◽

Download Full-text

Remarkable in vitro and in vivo activity of IMGN853, an antibody-drug conjugate targeting folate receptor alpha linked to the tubulin-disrupting maytansinoid DM4, in biologically aggressive (type II) endometrial cancers

Gynecologic Oncology ◽

10.1016/j.ygyno.2018.04.159 ◽

2018 ◽

Vol 149 ◽

pp. 70

Author(s):

G. Altwerger ◽

E. Bonazzoli ◽

S. Bellone ◽

T. Takata ◽

G. Menderes ◽

...

Keyword(s):

Folate Receptor ◽

Type Ii ◽

Antibody Drug Conjugate ◽

Folate Receptor Alpha ◽

Receptor Alpha ◽

Drug Conjugate ◽

Endometrial Cancers ◽

Download Full-text

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202, a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

Case Medical Research ◽

10.31525/ct1-nct04300556 ◽

2020 ◽

Author(s):

Keyword(s):

Folate Receptor ◽

Antibody Drug Conjugate ◽

Folate Receptor Alpha ◽

Receptor Alpha ◽

Drug Conjugate ◽

Tumor Types ◽

Download Full-text

FORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC)

Annals of Oncology ◽

10.1093/annonc/mdz250 ◽

2019 ◽

Vol 30 ◽

pp. v403 ◽

Author(s):

K. Moore ◽

A. Oza ◽

N. Colombo ◽

A. Oaknin ◽

G. Scambia ◽

...

Keyword(s):

Ovarian Cancer ◽

Folate Receptor ◽

Phase Iii ◽

Antibody Drug Conjugate ◽

Folate Receptor Alpha ◽

Receptor Alpha ◽

Drug Conjugate ◽

Platinum Resistant ◽

Phase Iii Study ◽

Download Full-text

Abstract 1770: Morab-202, a folate receptor alpha-targeted antibody-drug conjugate, shows a highly potent activity against a panel of FRA-expressing tumors

10.1158/1538-7445.am2018-1770 ◽

2018 ◽

Author(s):

Caroline Mignard ◽

Coralie DURIX ◽

Katherine Rybinski ◽

Xin Cheng ◽

Keiji Furuuchi ◽

...

Keyword(s):

Folate Receptor ◽

Antibody Drug Conjugate ◽

Folate Receptor Alpha ◽

Receptor Alpha ◽

Drug Conjugate ◽

Download Full-text

Abstract 3897: Stability and safety evaluation of STRO-002, a site-specific anti-folate receptor alpha antibody-drug conjugate for the potential treatment of ovarian and endometrial cancers

10.1158/1538-7445.sabcs18-3897 ◽

2019 ◽

Author(s):

Willy Solis ◽

Venita De Almeida ◽

Cristina Abrahams ◽

Xiaofan Li ◽

Tyler Heibeck ◽

...

Keyword(s):

Folate Receptor ◽

Safety Evaluation ◽

Potential Treatment ◽

Antibody Drug Conjugate ◽

Site Specific ◽

Receptor Alpha ◽

Drug Conjugate ◽

Endometrial Cancers ◽

A Site ◽

Download Full-text

Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models

Neoplasia ◽

10.1016/j.neo.2016.11.002 ◽

2016 ◽

Vol 18 (12) ◽

pp. 775-784 ◽

Author(s):

Jose F. Ponte ◽

Olga Ab ◽

Leanne Lanieri ◽

Jenny Lee ◽

Jennifer Coccia ◽

...

Keyword(s):

Ovarian Cancer ◽

Folate Receptor ◽

Standard Of Care ◽

Antibody Drug Conjugate ◽

Folate Receptor Alpha ◽

Receptor Alpha ◽

Drug Conjugate ◽

Cancer Models ◽

Download Full-text

Safety Profile of Mirvetuximab Soravtansine, a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Patients with Recurrent Ovarian Cancer

Gynecologic Oncology ◽

10.1016/j.ygyno.2019.11.066 ◽

2020 ◽

Vol 156 (3) ◽

pp. e15-e16

Author(s):

Kathleen G. Essel ◽

Lainie P. Martin ◽

David M. O’Malley ◽

Ursula Matulonis ◽

Jason A. Konner ◽

...

Keyword(s):

Ovarian Cancer ◽

Safety Profile ◽

Folate Receptor ◽

Recurrent Ovarian Cancer ◽

Antibody Drug Conjugate ◽

Folate Receptor Alpha ◽

Receptor Alpha ◽

Drug Conjugate ◽

Download Full-text

Mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with carboplatin and bevacizumab: Initial results from a phase Ib study in patients (pts) with ovarian cancer

Annals of Oncology ◽

10.1093/annonc/mdz250.036 ◽

2019 ◽

Vol 30 ◽

pp. v419-v420

Author(s):

D. O'Malley ◽

D. Richardson ◽

I.B. Vergote ◽

L. Gilbert ◽

L.P. Martin ◽

...

Keyword(s):

Ovarian Cancer ◽

Folate Receptor ◽

Antibody Drug Conjugate ◽

Folate Receptor Alpha ◽

Phase Ib ◽

Receptor Alpha ◽

Drug Conjugate ◽

Initial Results ◽

Download Full-text

Initial safety and activity findings from a phase IB escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant epithelial ovarian cancer (EOC) patients

Gynecologic Oncology ◽

10.1016/j.ygyno.2018.04.085 ◽

2018 ◽

Vol 149 ◽

pp. 38 ◽

Author(s):

U.A. Matulonis ◽

K.N. Moore ◽

L.P. Martin ◽

I.B. Vergote ◽

C.M. Castro ◽

...

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Folate Receptor ◽

Antibody Drug Conjugate ◽

Folate Receptor Alpha ◽

Phase Ib ◽

Receptor Alpha ◽

Drug Conjugate ◽

Platinum Resistant ◽

Download Full-text

Combination Regimens of Mirvetuximab Soravtansine, A Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, With Standard-Of-Care Agents Offer Promise for the Treatment of Ovarian Cancer

Health Care Current Reviews ◽

10.4172/2375-4273.1000195 ◽

2017 ◽

Vol 05 (02) ◽

Author(s):

Todd M Bauer

Keyword(s):

Ovarian Cancer ◽

Folate Receptor ◽

Standard Of Care ◽

Antibody Drug Conjugate ◽

Folate Receptor Alpha ◽

Receptor Alpha ◽

Drug Conjugate ◽

Combination Regimens ◽

Download Full-text